All posts by: MarksMan Healthcare

About MarksMan Healthcare

MarksMan Healthcare Communications

Healthcare decision making is usually characterized by a low degree of transparency. The demand for transparent decision processes can be fulfilled only when assessment, appraisal and decisions about health technologies are performed under a systematic construct of benefit assessment. The benefit of an intervention is often multidimensional and, thus, must be represented by several decision […]

Clinical research includes the traditional prospective clinical trials, cohort studies, and case-control studies, while outcomes research (OR) has now solidified itself as a separate class of clinical research. OR is an evolving and critical part of health sciences research due to its focus on the improvement of patient care in the practice setting. Evidence included […]

In many parts of the world, the value of medicines is measured by a unit called ‘Quality-Adjusted Life Year’ (QALY), a metric that health economists and others use to quantify the health benefits generated by a particular treatment. QALYs are often used by state-run health systems in many countries to help decide which drugs to […]

The fifth and last union budget for the present term of the BJP government focuses mainly on agriculture and rural economy. Besides, this budget  is also promoting education and health (1). Healthcare demands a national priority status and requires allocation of more funds to deliver affordable and quality healthcare services to all. Health budget was […]

The purpose of medicines is to improve patients’ lives. Despite the increasing number and scope of patient involvement initiatives, there is no accepted master framework for systematic patient involvement in pharma-led medicines development. Patient engagement is more productive, but inconsistent and fragmented on a broader level. Incorporating the patient perspective in healthcare research is strongly […]

While scientists, clinicians, and regulators play critical roles in understanding and communicating the benefits and risks of drugs/medical treatments, only patients live with their medical conditions and make choices regarding their personal care. They provide a unique voice and unique perspective. In recent years, more and more studies are focusing on patient reported outcomes (PROs). […]

The important role of food and nutrition in public health is being increasingly recognized as crucial for its potential impact on health-related quality of life (HRQoL) and economics, both at the societal and individual levels. Increasing epidemiological and scientific evidence demonstrates clear links between food and health maintenance/disease development. In developing countries, including India, morbidity […]

Specialty pharmaceuticals/drugs are a recent designation of pharmaceuticals that are classified as high-cost, high complexity and/or high touch. They are often biologics-“drugs derived from living cells” that are injectable or infused (although some are oral medications). Specialty drugs are used to treat complex or rare chronic conditions such as cancer, rheumatoid arthritis, hemophilia, HIV, psoriasis, inflammatory bowel disease (IBD) and Hepatitis […]

Health systems have developed at different speeds, and with differing degrees of complexity throughout the twentieth century, reflecting the diverse political and social conditions in each country. Notwithstanding their diversity, all systems, however, share a common reason for their existence, namely the improvement of health for their entire populations. To attain this goal a health […]